Journals / Klimik Dergisi / 2017 / Cilt: 30 - Sayı: 1

Successful Management of Chronic Hepatitis C Patient With Telaprevir-Associated Rash by Switching to Boceprevir

Telaprevir Tedavisiyle Deri Döküntüsü Gelişen Kronik Hepatit C'li Hastanın Boseprevirle Başarılı Tedavisi

Pages
41–42
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Klimik Dergisi 2017; 30(1): 36-7.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:After treatment of chronic hepatitis C with protease inhibitors such as telaprevir and boceprevir, increased sustained virologic response rates have been achieved compared to interferon and ribavirin.
📊
Key Findings & Data:However, serious adverse effects were increased due to these agents as well.
💡
Conclusion & Impact:Klimik Dergisi 2017; 30(1): 36-7.
🔬Design:Research Article
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Abstract

After treatment of chronic hepatitis C with protease inhibitors such as telaprevir and boceprevir, increased sustained virologic response rates have been achieved compared to interferon and ribavirin. However, serious adverse effects were increased due to these agents as well. One of the important adverse effects related to telaprevir is skin rash. A case of chronic hepatitis C with telaprevir-associated rash succesfully treated by switching to boceprevir was presented. Klimik Dergisi 2017; 30(1): 36-7.

Özet

Kronik hepatit C tedavisinde telaprevir ve boseprevir gibi proteaz inhibitörleri, pegile interferon ve ribavirin tedavisine göre kalıcı viral yanıt oranını artırmasına rağmen, tedaviye bağlı yan etkileri de artırmaktadır. Deri döküntüsü, telaprevire bağlı en önemli yan etkilerden birisidir. Bu yazıda telaprevir tedavisine bağlı olarak düzelmeyen eritematöz deri döküntüsü gelişen ve boseprevirle başarıyla tedavi edilen bir kronik hepatit C olgusu sunulmuştur. Klimik Dergisi 2017; 30(1): 36-7.

🔖

Cite This Article

HARMAN, R., HORASAN, E., YILDIRIM, E. (2022). Successful Management of Chronic Hepatitis C Patient With Telaprevir-Associated Rash by Switching to Boceprevir. Klimik Dergisi, Cilt: 30 - Sayı: 1, 41–42. https://ajindex.com/articles/573559

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S. An overview of HCV molecular biology, replication and immune responses. Virol J. 2011; 8: 161
  2. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010; 362(14): 1292-303
  3. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002; 36(5 Suppl. 1): S237-44
  4. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology. 2000; 31(4): 997-1004
  5. Tungol A, Rademacher K, Schafer JA. Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus. J Manag Care Pharm. 2011; 17(9): 685-94
  6. Cacoub P, Bourlière M, Lübbe J, et al. Dermatological side effects of hepatitis C and its treatment: Patient management in the era of direct-acting antivirals. J Hepatol. 2012; 56(2):455-63
  7. Naggie S, Sulkowski MS. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology. 2012; 142(6): 1324-34
  8. Marks KM, Jacobson IM. The first wave: HCV NS3 protease inhibitors telaprevir and boceprevir. Antivir Ther. 2012; 17(6 Pt B): 1119-31